MoonLake director resigns; CEO, CSO, CFO each to receive $4M equity grants in Jan 2025

MoonLake Immunotherapeutics

Dr. Kara Lassen resigns from Board effective Dec 31, 2024, due to new role at Roche Pharma; no dispute with Company.
Board approved long-term incentive program with annual equity grants; employees may elect restricted stock awards or stock options.
CEO Dr. Jorge Santos da Silva, CSO Dr. Kristian Reich, and CFO Matthias Bodenstedt each expected to receive $4M grant date fair value in Jan 2025, vesting over four years.
Board size reduced from 7 to 6 directors following resignation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.